Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01392495




Registration number
NCT01392495
Ethics application status
Date submitted
11/07/2011
Date registered
12/07/2011
Date last updated
10/08/2015

Titles & IDs
Public title
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
Scientific title
An Open-label Extension Study to CQTI571A2102 to Evaluate the Long-term Safety, Tolerability and Efficacy of QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension
Secondary ID [1] 0 0
2010-021960-14
Secondary ID [2] 0 0
CQTI571A2102E1
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Arterial Hypertension 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Imatinib

Experimental: QTI571 - Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).


Treatment: Drugs: Imatinib
200 mg or 400 mg qd
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Patients With Adverse Events, Serious Adverse Events and Deaths
Timepoint [1] 0 0
144 weeks
Secondary outcome [1] 0 0
Change From Baseline in the Six Minute Walk Distance (6MWD)
Timepoint [1] 0 0
baseline, 144 weeks
Secondary outcome [2] 0 0
Time to Clinical Worsening (TTCW) Endpoints
Timepoint [2] 0 0
144 weeks
Secondary outcome [3] 0 0
Medical Resource Utilization
Timepoint [3] 0 0
144 weeks

Eligibility
Key inclusion criteria
- Patients who completed in CQTI571A2102 clinical trial including all Study Completion
assessments at the end of study visit met the eligibility criteria for that study and
did not meet withdrawal criteria for safety reasons during study conduct
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with left ventricular ejection fraction (LVEF) < 45%

- Patients with thrombocytopenia, platelet count < 50 x109/L (50 x 103/µL).

- Patients with uncontrolled systemic arterial hypertension, systolic pressure > 160
mmHg or diastolic pressure > 90 mmHg.

- Patients with a QTcF > 450 ms for males and > 470 ms for females in the absence of
right bundle branch block.

Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2014
Sample size
Target
Accrual to date
Final
17
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Novartis Investigative Site - Darlinghurst
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New York
Country [2] 0 0
Belgium
State/province [2] 0 0
Leuven
Country [3] 0 0
Germany
State/province [3] 0 0
Hannover
Country [4] 0 0
Italy
State/province [4] 0 0
RM
Country [5] 0 0
Lithuania
State/province [5] 0 0
Vilnius
Country [6] 0 0
United Kingdom
State/province [6] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study was an extension to study CQTI571A2102 and was to evaluate the long-term safety,
tolerability and efficacy of QTI571 (imatinib) in severe pulmonary arterial hypertension
patients.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01392495
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01392495